Get the Stockscreener App
2.83
4.43%
0.12
Onkure Therapeutics Inc stock is traded at $2.83, with a volume of 59,579.
It is up +4.43% in the last 24 hours and up +26.34% over the past month.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
See More
Previous Close:
$2.71
Open:
$2.76
24h Volume:
59,579
Relative Volume:
0.50
Market Cap:
$36.35M
Revenue:
-
Net Income/Loss:
$-70.20M
P/E Ratio:
-0.0631
EPS:
-44.82
Net Cash Flow:
$-50.66M
1W Performance:
+11.86%
1M Performance:
+26.34%
6M Performance:
-48.17%
1Y Performance:
+0.00%
1-Day Range:
$2.70
$2.875
1-Week Range:
$2.49
$2.8929
52-Week Range:
$1.70
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Name
Onkure Therapeutics Inc
Sector
Industry
Phone
(720) 307-2892
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.83 | 37.83M | 0 | -70.20M | -50.66M | -44.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Evercore ISI | Outperform |
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Onkure Therapeutics Inc Stock (OKUR) Latest News
What earnings revisions data tells us about OnKure Therapeutics Inc.Global Markets & AI Enhanced Trading Alerts - Newser
Tick level data insight on OnKure Therapeutics Inc. volatilityTrade Risk Summary & Low Drawdown Trading Strategies - Newser
Key metrics from OnKure Therapeutics Inc.’s quarterly data2025 Growth vs Value & AI Powered Market Entry Strategies - Newser
How to recover losses in OnKure Therapeutics Inc. stockRisk Management & Weekly High Conviction Ideas - Newser
OnKure Therapeutics Inc. stock trend forecastWeekly Investment Recap & Capital Efficient Trading Techniques - Newser
Measuring OnKure Therapeutics Inc.’s beta against major indicesMarket Performance Recap & AI Driven Stock Price Forecasts - Newser
How to build a dashboard for OnKure Therapeutics Inc. stock2025 Trading Volume Trends & Risk Managed Trade Strategies - Newser
Published on: 2025-08-19 15:37:30 - Newser
How to build a custom watchlist for OnKure Therapeutics Inc.July 2025 Earnings & Safe Swing Trade Setups - Newser
Technical analysis overview for OnKure Therapeutics Inc. stockWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - Newser
Is OnKure Therapeutics Inc. forming a bottoming baseWeekly Investment Recap & Intraday High Probability Setup Alerts - Newser
Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky - Yahoo Finance
Published on: 2025-08-19 02:25:58 - Newser
Using data models to predict OnKure Therapeutics Inc. stock movementBull Run & Free Safe Entry Trade Signal Reports - Newser
How to monitor OnKure Therapeutics Inc. with trend dashboardsJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - Newser
Combining machine learning predictions for OnKure Therapeutics Inc.Gap Up & Weekly Momentum Stock Picks - Newser
Will OnKure Therapeutics Inc. stock recover after recent dropProfit Target & Weekly Momentum Stock Picks - Newser
Equities Analysts Offer Predictions for OKUR FY2025 Earnings - Defense World
What makes OnKure Therapeutics Inc. stock price move sharply2025 Valuation Update & Reliable Volume Spike Trade Alerts - Newser
Using data filters to optimize entry into OnKure Therapeutics Inc.Portfolio Value Report & Daily Stock Momentum Reports - Newser
OnKure Therapeutics Inc. stock outlook for YEAR2025 Trading Recap & Fast Gaining Stock Strategy Reports - Newser
Is OnKure Therapeutics Inc. Stock a Good Fit for Conservative InvestorsWeekly Profit Analysis & Technical Buy Zone Confirmations - Newser
Why OnKure Therapeutics Inc. stock attracts strong analyst attentionPortfolio Growth Summary & Weekly High Conviction Ideas - thegnnews.com
AI Tools Suggest OnKure Therapeutics Inc. May Outperform This WeekFree Stock Investment Discussion Area - beatles.ru
Applying big data sentiment scoring on OnKure Therapeutics Inc.July 2025 Short Interest & Risk Controlled Swing Alerts - Newser
Leerink Partnrs Has Positive Forecast for OKUR Q3 Earnings - Defense World
OnKure Therapeutics Inc. Price Holds Above Key Fib LevelJuly 2025 Trade Ideas & Growth Oriented Trade Recommendations - newsyoung.net
Published on: 2025-08-14 03:24:35 - Newser
Onkure Therapeutics Inc Stock (OKUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Onkure Therapeutics Inc Stock (OKUR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
| Cormorant Asset Management, LP | Former 10% Owner |
May 15 '25 |
Sale |
1.85 |
1,813,439 |
3,363,023 |
0 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
1,129,730 |
2,090,000 |
1,129,730 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
270,270 |
500,000 |
1,709,944 |
| Cormorant Asset Management, LP | 10% Owner |
May 12 '25 |
Sale |
1.99 |
24,300 |
48,236 |
1,813,439 |
| Saccomano Nicholas A | President and CEO |
Apr 07 '25 |
Sale |
2.67 |
516 |
1,378 |
3,682 |
| Saccomano Nicholas A | President and CEO |
Apr 04 '25 |
Sale |
3.33 |
358 |
1,191 |
4,198 |
| Leverone Jason A. | Chief Financial Officer |
Apr 07 '25 |
Sale |
2.67 |
1,844 |
4,925 |
13,209 |
| Leverone Jason A. | Chief Financial Officer |
Apr 04 '25 |
Sale |
3.33 |
1,278 |
4,253 |
15,053 |
| Leonard Braden Michael | 10% Owner |
Sep 25 '24 |
Buy |
1.50 |
68,746 |
102,872 |
3,457,395 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):